CEO and Co-Founder
Tom Isett is CEO of Commence Bio, Inc. (formerly WibiWorks Therapeutics), a pre-clinical stage biotech company developing cellular immunotherapies for inflammatory diseases and cancer. Tom has over 25 years of life science experience leading business units ranging in size from start-up to half-a-billion in revenues.
Prior to co-founding Commence Bio, he managed GE Life Sciences’ North American BioProcess organization and created a new business model for the company’s products and services that earned him the President’s Award for Growth (2014). Prior to GE, Tom led technology and business development activities for Lonza’s cell therapy contract development and manufacturing organization [CMO/CDMO]. Before that, he led a successful turnaround of Becton Dickinson’s [BD] Core Microbiology business unit. Tom’s growth initiatives ultimately led to the creation of two new businesses – one for Healthcare Associated Infections [HAIs], and another for Bioprocessing, the second of which he went on to lead to >$70M in sales.
Tom is a cum laude graduate of Drexel University, a proud father of identical twin sons, and a devoted husband of over 20 years.